Skip to content
Skip to navigation menu


Dr William Ford  -  PhD

Career Profile

  • 2002 - Cardiff University (Cardiff, UK) Lecturer in the Welsh School of Pharmacy. (promoted to Senior Lecturer in 2010)
  • 1998-2002 - University of Cambridge (Cambridge, UK) Department of Pharmacology Fellowship. Five year appointment with departmental operating grant (£72,000 over 5 years). Salary: £24,227
  • 1996-1998 - University of Alberta (Edmonton, Canada): Postdoctoral fellowship with Dr BI Jugdutt researching the pharmacology of angiotensin II in post-myocardial infarction remodeling, ischaemia-reperfusion injury and myocardial energy substrate metabolism.
  • 1994-96 - University of Alberta (Edmonton, Canada): Ciba-Giegy postdoctoral fellowship with Dr AS Clanachan, Dr R Schulz and Dr GD Lopaschuk. Researched adenosine A1 receptor and KATP-channel pharmacology in cardioprotection from ischaemia-reperfusion injury and myocardial energy substrate metabolism.



Robert Beamish award, Best paper of 1998
Recipient of the Robert Beamish award for the paper ‘Effect of the novel angiotensin II type 1 receptor antagonist L-158,809 on acute infarct expansion and acute anterior myocardial infarction in the dog’ published in the Canadian Journal of Cardiology

Heart and Stroke Foundation of Canada Fellowship award (1997)

Research interests

My research interests are spread across three main areas with common threads running through each area. Historically my background has been in cardiovascular pharmacology and more specifically in myocardial ischaemia-reperfusion injury. I have studied the how the rennin-angiotensin system affects short- and long-term recovery from myocardial ischaemia-reperfusion injury. More recently, I am engaged in investigating cardiovascular responses to endocannabinoids and trace amines. I am also involved in pulmonary research where we are studying the effects of modifying components of the inflammatory response (including the use of endocannabinoids) to reduce inflammation and allergen-induced bronchoconstriction. Study of the endocannainoid system also forms the basis of a new collaboration with Norgine to study inflammatory bowel disease.


Scientific service

Professional membership